Negative pressure therapy was associated with decreased surgical site infection. Negative pressure therapy offers significant potential for quality improvement.

gery have plateaued for both ulcerative colitis (UC) and Crohn' s disease (CD) while significant concerns have been raised about increasing rates of peri-operative complications. [2][3][4] Anti-tumor necrosis factor (anti-TNF) medications, in particular infliximab, have been shown to increase rates or perioperative infectious complications although this data remains controversial. 3,[8][9][10] It has also been suggested that concerns about anti-TNF related surgical complications is at least in part responsible for the increased rate of 3 stage surgery for UC in the United States. 10 Vedolizumab is an α4β7 anti-integrin antibody that has been increasingly used in both UC and CD. The α4β7 inhibi-

No abstract